Fish Declared Extinct in the 1980s Is 'Back from the Brink' with Over 200 Released into the Wild
The olive perchlet, a small oval-shaped fish with large eyes, was considered extinct in Victoria, Australia, in the 1980s after being last spotted in nature in 1929, according to the Australian Broadcasting Corporation. Now, the species is getting another shot at life and is "back from the brink."
Shenandoah Bruce with the North Central Catchment Management Authority told the Australian news outlet that the agency released "200 olive perchlet into Cameron's Creek in the Gunbower National Park."
The release occurred in January and reportedly marks the first time the fish has been reintroduced in the area since being labeled extinct.
According to the Australian Broadcasting Corporation, the olive perchlet plays a crucial role in the ecosystem, particularly in maintaining a healthy food system.
The 200 fish were bred in captivity with help from the Victorian Fisheries Authority.
Sam Fawke, senior technical officer for the Victorian Fisheries Authority, explained the importance of the fish species: "If we see these species across the board disappear, a lot are them are these small-bodied species, then we're going to see a major effect for the rest of those food webs."
The fish frequent wetlands and river systems and are known to eat tiny aquatic pests. They are also a food source for birds.
A Feb. 24 social media post from the North Central Catchment Management Authority shared that their recent survey of the olive perchlet released at a different location in Australia in October revealed "incredible results."
"From just 100 Olive Perchlet released last October, we discovered a whopping 855 individuals thriving, ranging from 14 mm to 49 mm," wrote the agency.
The New South Wales Department of Primary Industries states that the olive perchlet can grow to about 70 to 88 millimeters with an average size of about 2 inches.
The fish thrive in rivers, creeks, ponds, and swamps with slow or still waters and are often found on vegetation, logs, and dead branches.
The government agency states that the olive perchlet went extinct in the wild due to predation by other fish species, habitat degradation, and fluctuation in water levels.
Last month, researchers rediscovered another fish species in India after 85 years. The journal Zootaxa announced that a Chel snakehead, also known as Channa amphibious, was rediscovered after it was presumed to be extinct.
The freshwater species was absent for over eight decades, with the last recorded specimens collected between 1918 and 1933 in the Himalayan region of India. But in 2024, three specimens were collected on the banks of the Chel River in the town of Kalimpong in West Bengal.
Read the original article on People
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
UPI
2 hours ago
- UPI
Vaping better at helping smokers quit, study finds
Six-month smoking abstinence rates were three times higher among people using flavored nicotine-laced vape devices, compared to those given nicotine gum or lozenges, researchers reported Monday. Photo by lexphumirat/ Pixabay July 14 (UPI) -- Vaping might be more effective than traditional nicotine replacement therapies in helping people quit smoking, a new Australian study says. Six-month smoking abstinence rates were three times higher among people using flavored nicotine-laced vape devices, compared to those given nicotine gum or lozenges, researchers reported Monday in the Annals of Internal Medicine. Flavored vapes are restricted in the U.S. "Vaporized nicotine products were more effective than nicotine replacement therapy for smoking cessation," wrote the research team led by Ryan Courtney, an associate professor with the National Drug and Alcohol Research Center at the University of New South Wales in Australia. For the study, researchers recruited more than 1,000 Australians receiving government assistance and randomly assigned them to vaping or nicotine replacement. All were interested in trying to quit smoking. The vape group received an eight-week supply of vape juice in tobacco, menthol or fruit flavors, while the nicotine replacement group chose an eight-week supply of gum or lozenges. All participants also received automated text messages for five weeks that provided behavioral support for their quit attempt, researchers said. After six months, more than 28% of people in the vape group remained smoke-free, compared with a little under 10% of those in the nicotine gum or lozenge group, the study found. "In the current trial among people experiencing social disadvantage, vaporized nicotine products with flavor choice had greater effectiveness compared with nicotine replacement therapy gum or lozenge when provided in combination with minimal text-message behavioral support," researchers concluded. However, researchers noted that further study is needed to make sure that people will remain smoke-free long-term while using a vape device. It's also unknown whether people are swapping one health risk for another, researchers added. "Although current evidence suggests switching completely from cigarette smoking to (vaping) reduces health risks, the long-term health effects of vaping are largely unknown and data are emerging that demonstrate vaping can impact cardiovascular health," researchers wrote. The U.S. government has severely limited the number of flavored tobacco products that are legally available. Kid-friendly flavors like fruit, menthol and dessert, are sold illegally and have been fueling an explosion in retail sales of e-cigarettes, ABC News reported. More information Johns Hopkins has more on vaping. Copyright © 2025 HealthDay. All rights reserved.
New York Post
9 hours ago
- New York Post
Men can face double dementia risk if they have this hidden genetic mutation
A hidden genetic mutation could predict a man's likelihood of developing dementia. That's according to an Australian study led by Monash and Curtin Universities, which analyzed the medical data of thousands of Australians and Americans. Men who had a certain variant in the haemochromatosis (HFE) gene — which regulates iron levels in the body — were found to be at a higher risk of dementia, the researchers found. Previously healthy men over age 70 who have two copies of the variant, which is known as H63D, are at least twice — or up to four times — as likely to develop dementia. Having just one copy did not appear to elevate the risk. One in 36 men carry two copies of the mutation; one in three have just a single copy. 4 Men who had a certain variant in the haemochromatosis (HFE) gene were found to be at a higher risk of dementia, the researchers found. wirojsid – 'It is only men who have two copies of the variant that are at risk,' study co-author Professor John Olynyk from the Curtin Medical School told Fox News Digital. 'Women are not affected by the abnormality – we do not know why that is at the current point in time.' The study, which was published in the journal Neurology, used data from the ASPirin in Reducing Events in the Elderly (ASPREE) trial, which gathered health and aging data for 19,114 healthy older adults. Those who have the genetic variant can't change it, but it's possible that the 'brain pathways' it affects could be treated, Olynyk noted. 4 Those who have the genetic variant can't change it, but it's possible that the 'brain pathways' it affects could be treated, Olynyk noted. jamesteohart – 'The HFE gene is routinely tested for in most Western countries … when assessing people for haemochromatosis, a disorder that causes the body to absorb too much iron,' the doctor said. 'Our findings suggest that perhaps this testing could be offered to men more broadly.' Despite the fact that the HFE gene is responsible for controlling iron levels, the team found no direct link between iron and dementia risk. 'Our findings suggest that perhaps this testing could be offered to men more broadly.' Professor John Olynyk 'This points to other mechanisms at play, possibly involving the increased risk of brain injury from inflammation and cell damage in the body,' Olynyk added. More research is needed to determine why the heightened risk wasn't seen in women. 4 Despite the fact that the HFE gene is responsible for controlling iron levels, the team found no direct link between iron and dementia risk. djoronimo – 'Understanding why men with the double H63D variant are at higher risk could pave the way for more personalized approaches to prevention and treatment,' added co-author Professor Paul Lacaze from Monash University in a press release. The main limitation of the study, according to Olynyk, was that the study population was largely composed of Australians. 'Whether other populations exhibit the same effects is unclear,' he told Fox News Digital. 'Our work should be repeated in different countries to assess this.' 'Further research will be undertaken to try and determine the likely mechanism by which this anomaly causes dementia and what more we can do to reduce the impact of it.' 4 The main limitation of the study, according to Olynyk, was that the study population was largely composed of Australians. Monkey Business – Beyond this specific mutation, many other genetic and environmental factors can contribute to dementia risk, Olynyk noted. 'While genetic risk factors cannot be changed, the mechanisms by which these genetic abnormalities and environmental factors cause disease may well be modifiable to some extent, through adopting a healthy lifestyle and being proactive about maintaining an overall good state of health,' he said. To reduce risk, the researchers recommend adopting a healthy lifestyle that includes exercising regularly, eating a nutritious diet, minimizing alcohol intake, remaining mentally active, and seeing a doctor to address any medical problem known to increase the likelihood of dementia. The University of Melbourne, The Royal Children's Hospital, Murdoch Children's Research Institute and Fiona Stanley Hospital also contributed to the study.
Yahoo
5 days ago
- Yahoo
Adapting to funding and operational hurdles in today's clinical trials landscape
Against the backdrop of geopolitical tensions and economic measures such as tariffs, which are influencing supply chains across numerous industries, biotech companies are facing significant capital constraints, which in turn affect clinical trial activity. At the 12th Annual Outsourcing in Clinical Trials (OCT) UK and Ireland, which took place in June in London, UK, industry leaders delivered comprehensive insights and examined current market trends in today's clinical trials landscape both in the UK and on a global level. At the meeting, Aditya Kotta, head of business development of US and EU at global contract research organisation (CRO) Novotech, said investors are placing greater emphasis on later-stage data to overcome funding challenges. He said that in the case of early-stage assets, companies are now prioritising proof-of-concept data and streamlining their focus to achieve that swiftly and efficiently. In some cases, companies may concentrate resources on a single lead asset to maximise the likelihood of generating compelling data. Over the past several months, particularly in the last two quarters, Kotta has observed a noticeable shift among biotech companies that are pushing towards 'ex-US' strategies in clinical development, namely a switch towards regions such as Australia, Asia-Pacific, Eastern Europe, and even China for early-phase clinical trials. Such a trend reflects a growing strategic interest in diversifying trial geography to capitalise on the advantages offered by these regions, Kotta noted. According to Kotta, Australia has emerged as a leading location for early-phase trials due to a favourable regulatory environment, reduced costs, and high-quality data output. Countries such as Australia and New Zealand are also experiencing a lower rate of decline in clinical trial activity compared to the US. An analysis of clinical trial registries, including and Australian and New Zealand registries, showed a significant and notable decline in clinical trial activity, approximately 20% year over year, when comparing H1 2024 to H1 2025. 'Oncology trials typically make up about 30% to 40% of the market share of total clinical trials,' Kotta said. But between H1 2024 and H1 2025, there was an approximately 60% drop in oncology trial activity. Although nearly all therapeutic areas have seen reductions in clinical activity, some have demonstrated relatively strong resilience. Trials focused on obesity and RNA-based therapeutics continue to show robust performance and retain investor interest. Another key theme that was discussed at length at OCT UK & Ireland was the issue of patient and site engagement. The issue of non-enrolling clinical sites is not new and remains a consistent challenge across the industry, according to Esther Kitto, vice president of clinical operations at Resolution Therapeutics, which is developing a regenerative macrophage therapy for patients with end-stage liver disease. She acknowledged that Resolution's recruitment model, where patients are referred or follow a natural treatment pathway, has remained largely unchanged over the last two decades. However, the UK-based biotech is making strides to widen outreach and participation, expand the patient pool, increase recruitment rates, and reduce the number of inactive sites to address enrollment inefficiencies. Also advocating for revising old models of trial recruitment and management was TRI CEO Duncan Hall. The risk-based quality management (RBQM) employed by TRI analyses trial data to identify risks to trial success early, and allows coordinators to respond accordingly, replacing prior labour-intensive systems, as Hall told Clinical Trials Arena. 'RBQM adoption is on the rise…but the benefits from RBQM are not being fully realised,' Hall stated. He said TRI is now looking to incorporate AI techniques into its methodology, but human interaction will always be core to trial monitoring, with the patient-investigator relationship remaining key. Kitto said that recent findings show that nearly 30% of patients drop out of trials, not due to adverse events or safety concerns, but due to fatigue or lack of motivation. She added that patient retention is crucial, not just for ethical reasons, but also for maintaining data integrity. Patient advocates are keen to build closer ties with trial coordinators and industry, said Richard Stephens, a patient advocate from the Cancer Research Advocates Forum (CRAF-UK). He added that from patients to drug developers, it is in the interests of all parties involved to see timely and successful trial enrollment to support both the scientific goals of trials and the hopes held by participants for innovative cures and improved overall care. Stephens also called for closer collaboration between patient advocacy groups, especially across national boundaries, to facilitate greater enrollment through international trials. Kitto said that such collaborations go beyond simply sharing patient-facing documents such as information sheets and brochures. Resolution now shares full protocols with advocacy groups, enabling them to provide input on trial design aspects, including the number of interventions and procedures, as well as overall patient burden. She also stated that this inclusive approach aims to ensure that trials are more aligned with patient needs and experiences, promoting both transparency and engagement. Nonetheless, certain approaches to engaging with patients require greater forethought. The potential use of AI to enhance patient engagement was discussed in the second day's keynote address by Blanka Hezelova, associate director at GSK. In particular, Hezelova noted that trial forms used to establish informed patient consent are often viewed as complex, impersonal, and unclear with regard to data privacy. Hezelova stated that with the advent of advanced AI, consent forms can be personalised to individual participants, expressed in plain language, and driven by data. However, she warned: 'AI, unfortunately, does have a very serious risk of becoming coercive and manipulative,' and highlighted concerns around AI hallucinations and bias. Hezelova, therefore, stressed the continued need to train human trial coordinators and clinicians to offer in-person guidance as central to ensuring the trust of participants, key to addressing enrollment challenges. As regulatory bodies lag behind the pace of AI progress, she said developers and CROs must prepare for a transition period of clinical AI characterised by 'transformation, long-term changes'. In regard to clinical trial challenges specific to the UK, Kitto noted that the decentralised nature of the National Health Service (NHS) complicates trial setup timelines. Kitto proposed having centralised coordination within each hospital or NHS trust and a dedicated individual overseeing all clinical trial setup logistics, which could streamline these processes. Further challenge comes from limits on NHS staff capacity to engage in clinical trials. The research workforce is a major bottleneck to NHS-led trials, according to Karolin Kroese, programme office lead at the Experimental Cancer Medicine Centre Network. The issue is compounded by a fundamental lack of career growth opportunities, said Dr Davy Yeung, COO at British CRO TCR Solutions. 'There is no career pathway for research nurses,' he stated, with many seeking advancement through other careers such as academia. However, recent changes to the UK Medicines and Healthcare products Regulatory Agency (MHRA's) Innovative Licensing and Access Pathway (ILAP) can be expected to accelerate patient access to new medicines through improved collaboration between national healthcare systems and drug developers, as per Dr Austin Smith, CMO of Sweden-based Oxcia. Expected updates to the 2004 Medicines for Human Use (Clinical Trials) Regulations to facilitate medicine manufacture near points of patient care were cause for optimism, according to Shasheen Payoe, PhD, clinical account manager at Germany-based Miltenyi Biotec. With new clinical trial regulations on the horizon, there is an opportunity to move the industry forward, said Sarah Deely, director of country and site operations at Biogen. Biogen is proactively engaging with key regulatory and policy stakeholders, including the MHRA, National Institute for Health and Care Research (NIHR), and the Association of the British Pharmaceutical Industry (ABPI), not just as participants, but as collaborators in shaping these regulations. Deely added that Biogen is also deeply involved in the rollout of the Clinical Research Delivery Centres (CRDCs)—regional hubs established across the UK to facilitate and accelerate research. She stated that the company, which is conducting trials in rare diseases, co-develops its protocols with global and UK-based medical experts to reduce the burden on both patients and sites. Deely added that the aim is to avoid unnecessary amendments later and to align protocols with UK healthcare realities, including post-approval reimbursement and long-term care needs. Additionally, some UK hospitals have embedded patient and public involvement (PPI) teams to link sponsors, medical experts, and patients to ensure operational efficiency and patient-centricity. The UK's NHS should be more fundamentally centred around clinical trials through collaboration with industry to foster greater innovation in the country's pharmaceutical sector, said Stephens. Though he recognised the strain on resources experienced by many hospitals, Stephens remained convinced the UK could shore up its clinical trials sector. "Adapting to funding and operational hurdles in today's clinical trials landscape" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
